Clinical trials
Prostate Cancer (Adenocarcinoma) clinical trials
Below are recruiting prostate cancer (adenocarcinoma) clinical trials, each written for real people, not researchers. We’re tracking 539 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06957691RecruitingPhase 2
Fezolinetant for hot flashes in men on hormone therapy
This study tests whether a medication called fezolinetant can reduce hot flashes in men with prostate cancer caused by hormone therapy (ADT). If you have frequent, bothersome hot flashes, this treatment may help.
Boston, MassachusettsAges 40 years+ - NCT06967961Recruiting
Looking for cancer cells that carry two markers in the blood
This trial is studying a special type of cell that shows up in the blood of people with certain advanced cancers. It aims to find out if these cells can help doctors better understand the cancer and guide treatment.
ToulouseAges 18 years+ - NCT06990542RecruitingPhase 2
Focused radiation therapy for intermediate and high-risk prostate cancer
This trial tests a more precise radiation therapy that targets tumors seen on MRI or special scans, aiming to treat prostate cancer while reducing side effects. It is for men who have not had prostate surgery or previous radiation to the area.
La Jolla, CaliforniaAges 18 years+ - NCT06995053Recruiting
Prostate cancer radiation therapy with motion monitoring
This trial tests a precise radiation technique for prostate cancer that tracks the prostate during treatment. It aims to deliver higher radiation doses more safely, which may improve outcomes.
Los Angeles, CaliforniaAges 18 years+ - NCT06999187RecruitingPhase 1
Study of DR-0202 for advanced solid tumors after multiple treatments
This trial tests a new drug, DR-0202, for people with certain advanced cancers that have not responded to at least two prior treatments. It may be an option if standard treatments are no longer working.
Denver, ColoradoAges 18 years+ - NCT07015138Recruiting
Comparing two radiation approaches for prostate cancer that has spread a little
This trial is testing whether giving radiation to all spots of cancer that show up on a PSMA PET scan works better than giving radiation only to the main tumor in the prostate. It is for men whose prostate cancer has spread to a few other places (up to 10 spots).
Beijing, Beijing MunicipalityAges 18–85 - NCT07025369RecruitingPhase 2
Hormone pill before PSMA scan for high-risk prostate cancer
This trial tests if giving a short-term hormone pill (relugolix) before a special PSMA PET/CT scan makes the scan clearer for men with high-risk prostate cancer. It may help doctors better see where the cancer is.
Scottsdale, ArizonaAges 18 years+ - NCT07027124RecruitingPhase 2
High-risk prostate cancer treatment before and after surgery
This trial tests a combination of hormone therapy, a targeted pill (Darolutamide), and an immunotherapy drug (Pembrolizumab) before and after surgery for men with high-risk prostate cancer that has specific genetic features. The goal is to see if this approach helps prevent the cancer from coming back.
New York, New YorkAges 18 years+ - NCT07038304RecruitingPhase 2
Radiation for cancer growth in prostate cancer that stopped responding to hormones
This trial tests whether giving precise radiation to a few spots of cancer growth can help control prostate cancer that has stopped responding to hormone therapy. It is for people with up to 3 growing or new spots of cancer on a special scan.
GroningenAges 18 years+ - NCT07047495Recruiting
Personalized radiation therapy for early breast cancer
This trial is testing a way to personalize radiation therapy for people with early-stage breast cancer. It may help make treatment more precise and reduce side effects.
Milan, ItalyAges 18 years+ - NCT07054346RecruitingPhase 1
Comparing two radiation drugs for high-risk prostate cancer before surgery
This trial tests two radioactive drugs (Lu-177 and Ac-225 PSMA-617) given before prostate removal surgery in men with high-risk prostate cancer that hasn't spread far. The goal is to see which drug works better at targeting cancer cells.
San Francisco, CaliforniaAges 18 years+ - NCT07090148RecruitingPhase 1
Vaccine plus immunotherapy for prostate cancer that has returned
This trial tests a combination of a DNA vaccine (pTVG-HP) and an immunotherapy drug (nivolumab) along with targeted radiation or ablation of remaining cancer spots. It is for men whose prostate cancer has come back after surgery but hasn't spread widely.
Madison, WisconsinAges 18 years+ - NCT07112781Recruiting
Single dose radiation for early prostate cancer
This trial tests whether a single, high dose of radiation can treat low- to intermediate-risk prostate cancer. It may be a shorter and more convenient option for eligible patients.
MoscowAges 18 years+ - NCT07115914Recruiting
PSMA PET scan to monitor prostate cancer after focal therapy
This trial uses a special PET scan (PSMA PET) to check if prostate cancer returns after focused treatment (focal therapy). It may help find any remaining cancer that standard scans miss.
Chicago, IllinoisAges 18 years+ - NCT07115992Recruiting
Surgery with or without radiation for prostate cancer
This trial compares radical prostatectomy (surgery to remove the prostate) alone versus surgery plus pelvic lymph node removal, with or without additional radiation, for men with intermediate- or high-risk prostate cancer that has not spread. It aims to see which approach is more effective and safe.
ShanghaiAges 18–80 - NCT07129551Recruiting
PSMA-guided surgery for prostate cancer with lymph node spread
This study looks at how well a special type of surgery, guided by PSMA-PET scans, works for men with prostate cancer that has spread to a small number of lymph nodes in the pelvis. It aims to improve outcomes and quality of life.
Hamburg, Free and Hanseatic City of HamburgAges 18–78 - NCT07145255RecruitingPhase 1/Phase 2
Study of MBRC-201 for advanced solid tumors
This trial tests a new drug, MBRC-201, for people with advanced solid tumors that have not responded to standard treatments. The goal is to find the best dose and see if it helps shrink tumors or slow their growth.
San Francisco, CaliforniaAges 18 years+ - NCT07168616Recruiting
PSMA PET imaging for active surveillance in low-risk prostate cancer
This study uses a special imaging test (PSMA PET/CT) to better see if men with low-risk prostate cancer are good candidates for active surveillance (monitoring instead of immediate treatment). It helps doctors decide if watching the cancer closely is safe.
Istanbul, TurkeyAges 18 years+ - NCT07179783RecruitingPhase 2
Sacituzumab Tirumotecan and Tagitanlimab for aggressive prostate cancer
This trial tests a combination of two drugs for men with aggressive or neuroendocrine prostate cancer that has worsened after previous hormone therapy. The goal is to see if the combination can shrink tumors or slow the disease.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07182279RecruitingPhase 1/Phase 2
Internal radiation before prostate surgery for high-risk cancer
This trial tests a treatment approach for newly diagnosed, high-risk prostate cancer. You would receive a short course of internal radiation (high-dose-rate brachytherapy) before surgery to remove your prostate. The goal is to see if this combination is safe and works better than surgery alone.
Houston, TexasAges 40 years+ - NCT07196488Recruiting
Co-learning program for prostate cancer patients and their spouses
This trial tests a learning program for couples where one partner has prostate cancer. It aims to help patients and their spouses learn together and support each other.
KeelungAges 20–90 - NCT07209878RecruitingPhase 2/Phase 3
PET scan vs. MRI for prostate cancer diagnosis
This trial compares two types of imaging scans (a PSMA PET scan and an MRI) to see which is better at finding prostate cancer. You may be able to join if you are scheduled for prostate removal surgery and haven't started cancer treatment yet.
Fuzhou, FujianAges 18–80 - NCT07219147RecruitingPhase 1
Combination treatment for advanced prostate cancer
This trial tests a combination of two treatments for advanced prostate cancer that has stopped responding to hormone therapy. One treatment is a targeted radiation therapy (177Lu-PSMA-617) and the other is an immunotherapy (sipuleucel-T) that helps your immune system fight the cancer.
Duarte, CaliforniaAges 18 years+ - NCT07219303Recruiting
Adaptive radiation therapy for intermediate- or high-risk prostate cancer
This trial tests a type of radiation that adjusts to changes in your prostate during treatment. It aims to improve accuracy and reduce side effects for men with intermediate- or high-risk prostate cancer.
Philadelphia, PennsylvaniaAges 18 years+
Hear when a new Prostate Cancer (Adenocarcinoma) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate cancer (adenocarcinoma)?
- Yes. Clin2 currently lists 539 recruiting prostate cancer (adenocarcinoma) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate cancer (adenocarcinoma) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate cancer (adenocarcinoma) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.